Pregnancy outcomes in in vitro fertilization in 17-alpha-hydroxylase deficiency
Annika van Oosbree, M.S.-IV,
Ayesha Asif, O.M.S.-IV,
Sarah Hmaidan, O.D.,
Alan DeCherney, M.D.
Affiliations
Annika van Oosbree, M.S.-IV
Reproductive Endocrinology and Infertility, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; University of South Dakota Sanford School of Medicine, Vermillion, South Dakota; Reprint requests: Annika van Oosbree, Department of Reproductive Endocrinology and Infertility, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.
Ayesha Asif, O.M.S.-IV
Reproductive Endocrinology and Infertility, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; Lake Erie College of Osteopathic Medicine, Bradenton, Florida
Sarah Hmaidan, O.D.
Reproductive Endocrinology and Infertility, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; Vanderbilt University, Nashville, Tennessee
Alan DeCherney, M.D.
Reproductive Endocrinology and Infertility, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
Since the first case of 17-alpha-hydroxylase-deficiency (17-OHD) was described in 1966, a number of cases have been reported with a clinical picture of hypertension, hypokalemia, and hypogonadism. Infertility is a major concern for some of these individuals. This mini-review aims to detail the components of this disorder that affect fertility and focus on the recent acceleration in the success of achieving live births, as well as highlight the unsuccessful attempts. The data supporting successful live births remains limited, but existing evidence suggests that in vitro fertilization can be used in conjunction with hormone replacement therapy and steroid suppression to achieve live birth in patients with infertility from 17-OHD.